NasdaqGM - Nasdaq Real Time Price USD

Evolus, Inc. (EOLS)

Compare
15.26 +0.55 (+3.74%)
As of 3:31 PM EDT. Market Open.
Loading Chart for EOLS
DELL
  • Previous Close 14.71
  • Open 14.54
  • Bid 15.25 x 100
  • Ask 15.31 x 100
  • Day's Range 14.52 - 15.59
  • 52 Week Range 7.44 - 16.29
  • Volume 320,394
  • Avg. Volume 504,974
  • Market Cap (intraday) 962.822M
  • Beta (5Y Monthly) 1.32
  • PE Ratio (TTM) --
  • EPS (TTM) -0.90
  • Earnings Date Nov 5, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.43

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

www.evolus.com

304

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EOLS

View More

Performance Overview: EOLS

Trailing total returns as of 9/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EOLS
44.92%
S&P 500
14.53%

1-Year Return

EOLS
60.29%
S&P 500
22.56%

3-Year Return

EOLS
70.31%
S&P 500
21.02%

5-Year Return

EOLS
1.55%
S&P 500
83.40%

Compare To: EOLS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EOLS

View More

Valuation Measures

Annual
As of 9/6/2024
  • Market Cap

    928.12M

  • Enterprise Value

    961.20M

  • Trailing P/E

    --

  • Forward P/E

    98.04

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.65

  • Price/Book (mrq)

    48.05

  • Enterprise Value/Revenue

    4.05

  • Enterprise Value/EBITDA

    -21.50

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.43%

  • Return on Assets (ttm)

    -9.36%

  • Return on Equity (ttm)

    -861.68%

  • Revenue (ttm)

    237.26M

  • Net Income Avi to Common (ttm)

    -53.21M

  • Diluted EPS (ttm)

    -0.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    93.67M

  • Total Debt/Equity (mrq)

    656.27%

  • Levered Free Cash Flow (ttm)

    -2.13M

Research Analysis: EOLS

View More

Company Insights: EOLS

Research Reports: EOLS

View More

People Also Watch